Axsome Therapeutics received an "Outperform" rating from BMO Capital due to significant progress in its drug pipeline, including FDA acceptance of its NDA for AXS-12, a narcolepsy treatment with a PDUFA date set for May 1, 2027. The company is also advancing a Phase 3 trial for an ADHD drug, broadening its clinical programs. These developments have driven a 30.1% year-to-date stock rally, outperforming the industry average and supporting positive analyst sentiment.
Carbios has successfully produced its 100th batch at its Clermont-Ferrand demonstration plant, validating its enzymatic 'Fiber-to-Fiber' biorecycling process for complex post-consumer textile waste. Achieving over 95% conversion within 24 hours, the ...
Viridien, a global leader in advanced digital and Earth data technologies, will announce its financial results for the second quarter of 2026 on July 30 after market close. The company will publish a press release and presentation at 17:45 French tim...
The global enterprise carbon management software market, valued at $16.7 billion in 2024, is projected to grow to $42.2 billion by 2034 at a CAGR of 9.73%. Growth is driven by increasing corporate net-zero commitments, stricter climate regulations, a...
The PUMP token from Pump.fun surged over 30% in the past week, driven by a $1.5 million purchase from crypto influencer Ansem and a $410 million token buyback initiative that has burned over 151 billion tokens. Daily trading volume spiked by more tha...
In the second quarter of 2026, Class A shares of the Alger Spectra Fund outperformed the Russell 3000 Growth Index. Key contributors to this positive performance included Nebius Group N.V., Astera Labs, and Western Digital Corporation, while GFL Envi...
